<table className="table"><caption><p>Subtypes of Cardiac Amyloidosis</p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Subtype</p></th><th colSpan="1" rowSpan="1"><p>Demographics</p></th><th colSpan="1" rowSpan="1"><p>Clinical Manifestations</p></th><th colSpan="1" rowSpan="1"><p>Diagnostic Tests</p></th><th colSpan="1" rowSpan="1"><p>Therapy</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p>AL</p></td><td colSpan="1" rowSpan="1"><p>M â‰ˆ F, aged 40-80 y</p></td><td colSpan="1" rowSpan="1"><p>Nephrotic syndrome, cardiomyopathy, hepatosplenomegaly, neuropathy, carpal tunnel syndrome, bleeding diathesis, periorbital purpura, macroglossia</p></td><td colSpan="1" rowSpan="1"><p>Analysis for clonal plasma cell dyscrasias with SPEP, UPEP, serum/urine immunofixation, and serum FLC testing</p><p>Bone marrow biopsy</p><p>CMR imaging with LGE</p><p>Endomyocardial biopsy or other tissue biopsy</p></td><td colSpan="1" rowSpan="1"><p>Treatment of plasma cell dyscrasias</p><p>Cardiac transplantation in selected cases</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p>ATTR</p></td><td colSpan="1" rowSpan="1"><p>h-ATTR: M &gt;&gt; F, aged 55-75 y</p><p>wt-ATTR: M &gt;&gt;&gt; F, aged 65-95 y</p></td><td colSpan="1" rowSpan="1"><p>Cardiomyopathy, carpal tunnel syndrome, spinal stenosis, neuropathy</p></td><td colSpan="1" rowSpan="1"><p>CMR imaging with LGE</p><p>99m-Technetium pyrophosphate scintigraphy</p><p>Endomyocardial biopsy (controversial)</p><p>Genetic testing</p></td><td colSpan="1" rowSpan="1"><p>Tafamidis</p><p>Diflunisal (off label)</p><p>Patisiran (neuropathy)</p><p>Inotersen (neuropathy)</p><p>Liver or heart-liver transplantation</p></td></tr></tbody></table>